Preventing pregnant women from participating in clinical trials is well intentioned but misguided. Pregnant women are a “vulnerable” population in research due to their relationship with the fetus who cannot consent to participation.1 For ethical committee approval, study interventions in pregnancy must directly benefit or pose minimal risk to the mother and fetus, and often consent must be obtained from both parents. As a result, institutional review boards and investigators frequently limit the inclusion of pregnant women in trials even when they may benefit from study interventions. Thus, more than 80% of pregnant patients are routinely prescribed therapies that have not been studied in pregnancy.2 Given the limited amount of safety data, it is largely unknown if medications could harm patients, which interventions are truly effective, or whether it is safe to delay treatment until after pregnancy.
Heyrana K, Byers HM, Stratton P. Increasing the Participation of Pregnant Women in Clinical Trials. JAMA. 2018;320(20):2077–2078. doi:10.1001/jama.2018.17716
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.